Amarantus Subsidiary MANF Therapeutics Announces P
Post# of 30066
(Total Views: 477)
Posted On: 01/03/2018 8:04:27 AM
Amarantus Subsidiary MANF Therapeutics Announces Patent Issuances in Europe and China Covering MANF as a Treatment and Biomarker in Diabetes and Publication of MANF Human Pre-Diabetes and Diabetes Biomarker Data
Download as PDF
JANUARY 03, 2018
Patents extend MANF Therapeutics' exclusivity for use of MANF as a treatment and a biomarker for beta cell disorders in Europe and China into 2032
List of diseases covered by patents include Type-1 diabetes, Type-2 diabetes and Wolfram's Syndrome
Publication opens potential to diagnose and monitor pre-diabetes and diabetes patients
SAN FRANCISCO, Jan. 03, 2018 (GLOBE NEWSWIRE) -- via OTC PR Wire -- Amarantus Bioscience Holdings, Inc. (OTCPK:AMBS), a US-based biotechnology holding company with wholly-owned subsidiaries developing first-in-class orphan neurologic, regenerative medicine and ophthalmic therapies, today announced that its wholly-owned subsidiary MANF Therapeutics, Inc. was issued patents in Europe and China entitled "Beta Cell Disorders" covering the therapeutic and biomarker use of mesencephalic astrocyte-derived neurotrophic factor (MANF) in beta cell disorders, including pre-diabetes, Type-1 diabetes, Type-2 diabetes and Wolfram's Syndrome. The patents extend exclusivity for the therapeutic and biomarker use of MANF in Europe and China into 2032.
Additionally, the Company announced the publication of a peer-reviewed article in Endocrine Journal entitled "Circulating mesencephalic astrocyte-derived neurotrophic factor is increased in newly diagnosed prediabetic and diabetic patients, and is associated with insulin resistance" describing how a MANF-based ELISA was used to identify levels of circulating MANF protein in pre-diabetes and diabetes patients. Results from these tests demonstrated that blood levels of MANF were correlated with insulin sensitivity indices in pre-diabetes patients in the 257 participant study. The authors of the publication concluded that MANF serum levels were higher in patients with newly diagnosed pre-diabetes and type-2 diabetes than in non-glucose tolerant controls, and that MANF appears to be associated with the Matsuda Index, QUICKI and HOMA-IR in pre-diabetes patients.
Download as PDF
JANUARY 03, 2018
Patents extend MANF Therapeutics' exclusivity for use of MANF as a treatment and a biomarker for beta cell disorders in Europe and China into 2032
List of diseases covered by patents include Type-1 diabetes, Type-2 diabetes and Wolfram's Syndrome
Publication opens potential to diagnose and monitor pre-diabetes and diabetes patients
SAN FRANCISCO, Jan. 03, 2018 (GLOBE NEWSWIRE) -- via OTC PR Wire -- Amarantus Bioscience Holdings, Inc. (OTCPK:AMBS), a US-based biotechnology holding company with wholly-owned subsidiaries developing first-in-class orphan neurologic, regenerative medicine and ophthalmic therapies, today announced that its wholly-owned subsidiary MANF Therapeutics, Inc. was issued patents in Europe and China entitled "Beta Cell Disorders" covering the therapeutic and biomarker use of mesencephalic astrocyte-derived neurotrophic factor (MANF) in beta cell disorders, including pre-diabetes, Type-1 diabetes, Type-2 diabetes and Wolfram's Syndrome. The patents extend exclusivity for the therapeutic and biomarker use of MANF in Europe and China into 2032.
Additionally, the Company announced the publication of a peer-reviewed article in Endocrine Journal entitled "Circulating mesencephalic astrocyte-derived neurotrophic factor is increased in newly diagnosed prediabetic and diabetic patients, and is associated with insulin resistance" describing how a MANF-based ELISA was used to identify levels of circulating MANF protein in pre-diabetes and diabetes patients. Results from these tests demonstrated that blood levels of MANF were correlated with insulin sensitivity indices in pre-diabetes patients in the 257 participant study. The authors of the publication concluded that MANF serum levels were higher in patients with newly diagnosed pre-diabetes and type-2 diabetes than in non-glucose tolerant controls, and that MANF appears to be associated with the Matsuda Index, QUICKI and HOMA-IR in pre-diabetes patients.
(2)
(0)